Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | KIF11 | P52732 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11912869 | 0.93 | KIF11 (0.70) | TP53MAPTKIF11SMN1; SMN2ABCG2 | |
| SCHEMBL22238481 | 0.92 | TP53 (0.64) | TP53MAPTKIF11SMN1; SMN2ABCG2 | |
| SCHEMBL20704585 | 0.90 | TP53 (0.66) | TP53MAPTKIF11SMN1; SMN2ABCG2 | |
| SCHEMBL20704712 | 0.90 | TP53 (0.66) | TP53MAPTKIF11SMN1; SMN2ABCG2 | |
| SCHEMBL904374 | 0.90 | TP53 (0.66) | TP53MAPTKIF11SMN1; SMN2ABCG2 | |
| SCHEMBL765043 | 0.90 | TP53 (0.59) | TP53MAPTKIF11SMN1; SMN2ABCG2 | |
| SCHEMBL8402856 | 0.90 | TP53 (0.61) | TP53MAPTKIF11SMN1; SMN2ABCG2 | |
| SCHEMBL8402676 | 0.90 | TP53 (0.61) | TP53MAPTKIF11SMN1; SMN2ABCG2 | |
| SCHEMBL8402811 | 0.90 | TP53 (0.68) | TP53MAPTKIF11SMN1; SMN2ABCG2 | |
| SCHEMBL764584 | 0.89 | TP53 (0.67) | TP53MAPTKIF11SMN1; SMN2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | TP53 16/4885MAPT 3328/4885KIF11 2569/4885 |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | TP53 16/4885MAPT 3328/4885KIF11 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.